Fig. 1: Neratinib (N) containing anti-HER2 regimen shows superior anti-tumor efficacy than trastuzumab (T) and pertuzumab (P) in BT474 cell-derived xenograft model. | npj Breast Cancer

Fig. 1: Neratinib (N) containing anti-HER2 regimen shows superior anti-tumor efficacy than trastuzumab (T) and pertuzumab (P) in BT474 cell-derived xenograft model.

From: Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models

Fig. 1: Neratinib (N) containing anti-HER2 regimen shows superior anti-tumor efficacy than trastuzumab (T) and pertuzumab (P) in BT474 cell-derived xenograft model.

a Average growth curves of tumors treated with Vehicle, N, T, P, N + T, or P + T (n = 9–14). Results are presented as mean tumor volume ± SEM. Kaplan–Meier analysis of b time to tumor progression in mice treated with different anti-HER2 therapies, c time to complete response in mice treated with N, T, or N + T, d time to complete response in mice treated with T, P, or T + P, and e time to tumor regression and f time to complete response in mice treated with N + T or P + T. Shaded areas represent point-wise 95% confidence regions, calculated using the loglog transform. P values are indicated on plots, Wilcoxon test; Veh Vehicle, ED estrogen deprivation.

Back to article page